Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 4, 2000, Pages 206-212

  Hakki, Sam I ^a   Camblin, John ^a   Fareed, Jawed ^b   Hoppensteadt, Debra A ^b   Abdullah, Hani ^c   Hamadeh, Ossama ^c   Wright, Terry ^c   Nasseri, Andrew F ^d  

^a Bay Pines Medical Center   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Bay Pines Research Foundation   (United States)

Author keywords

Enoxaparin; Postoperative bleeding; Tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE CALCULATION; HUMAN; ORTHOPEDIC SURGERY; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; STATISTICAL ANALYSIS; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG MONITORING; ENOXAPARIN; FACTOR XA; FIBRINOLYTIC AGENTS; HEMORRHAGE; LIPOPROTEINS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SURGICAL PROCEDURES, OPERATIVE; TIME FACTORS; VENOUS THROMBOSIS;

EID: 0034541256     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600405     Document Type: Article

References (45)

1. Antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin
2. Experimental haemorrhagic effect of twodomain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin
3. Differential effect of unfractionated heparin and low molecular weight heparin on intravenous tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action
4. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIaa activities, and D-dimer plasma levels in pationts receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery
5. Neuraxial block and low-molecular weight heparin: Balancing perioperative analgesia and thromboprophylaxis
6. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement
7. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs)
8. Comparative effects of Enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor
9. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxsis in patients treated with low molecular weight heparin
10. Tissue factor pathway inhibitor: Potential therapeutic applications
11. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis
12. Experimental haemorrhagic effect of two domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin
13. Enoxaparin, a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery
14. Thromboembolic disease in orthopaedic surgery
15. An analysis of blood management in patients having a total hip or knee arthroplasty
16. Monitoring the anticoagulanat effects of a low molecular weight heparin preparation
17. Monitoring of low-molecular-weight heparins in cardiovascular disease
18. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in effective hip and knee replacement?
19. Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis
20. Efficacy and safety of enoxaparin for the prevention of deep vein thrombosis after hip replacement surgery
21. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
22. Prevention of deep vein thrombosis after total hip replacement
23. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement
24. Prevention of deep-vein thrombosis after total hip replacement
25. Efficacy of low doses of heparin in prevention of deep vein thrombosis after major surgery: A double-blind randomized study
26. Attitudes to, and utilization of, low molecular weight heparins in joint replacement surgery
27. Tissue factor antigen levels in various biological fluids
28. Haemorrhagic effects of unfractionated and two low molecular weight heparins, enoxaparin and fragmin, in rats
29. A comparison study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers
30. Comparison of two low-molecular-weight heparin for the prevention of postoperative venous thromboembolism after elective hip surgery
31. Comparative double-blind study of two dosage regimens of low-molecular weight heparin in elderly patients with a fracture of the neck of the femur
32. Clexane (enoxaparin) or Fragmin (dalteparin) for thrombolytic prevention in hip replacement surgery?
33. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor
34. Heparin realistic tissue factor pathway inhibitor during interventional cardiovascular procedures
35. Platelet factor 4 and antithrombin are not the sole determinants of the heparinzation response
36. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins?
37. The role of tissue factor pathway inhibitor in the medication of the antithrombotic actions of heparin and low-molecular-weight heparin
38. Pharmacological profiling of recombinant tissue factor pathway inhibitor
39. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor
40. Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin
41. Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo
42. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro- modulatory action of glycosaminoglycans
43. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II
44. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin
45. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin